Cell Therapy

R&D

Allogeneic cell therapy isn’t dead, with Brian Culley

Lineage Cell Therapeutics' Brian Culley discusses allogeneic cell therapy, even beyond the traditional cell therapy realm of oncology.

Oncology

Engineering “smarter” cells, with Tim Lu

Senti Bio's Tim Lu discusses “logic-gated” cells, which have multiple receptors allowing them to attack cancer cells while leaving healthy cells alone

News

Galapagos abandons cell therapy, putting 365 jobs at risk

Galapagos' difficult year has continued with a decision to wind down its cell therapy business as it seeks 'transformative' deals for its drugs unit.

R&D

Bolstering CAR-T therapies by tackling CRS, with Teresa Whal...

In interview with Teresa Whalen, the CEO of CytoAgents, a clinical-stage drug development company working on a treatment for cytokine release syndrome

News

Gilead buys in vivo cell therapy firm Interius for $350m

Gilead's Kite unit has reached an agreement to buy Interius BioTherapeutics, boosting its in vivo cell therapy credentials.

Partner Content

7th Cell Therapy Analytical Development Summit

Join us in fast-tracking the next era of safe, potent, and robust cell therapies to market!

Cell Therapy

Editor's Picks